Transcend Inc not too long ago launched Transcend Micro, a CPAP that weighs underneath a half pound and measures lower than 4 inches.
“Once we designed the brand new Transcend Micro, we didn’t wish to merely introduce one other transportable CPAP. We challenged ourselves to ship a CPAP machine that displays the approach to life and preferences of as we speak’s customers,” says William Brown, chief monetary officer at Transcend, in a launch. “Small, transportable, handy, customizable, and sensible are advantages and options most individuals need from their machine. The brand new Transcend Micro checks all these packing containers, from the graceful design to add-on equipment and sensible options such because the Bluetooth performance that permits customers to trace their sleep remedy information through a cell app.” Learn extra right here.
Sunosi improves cognitive perform in obstructive sleep apnea sufferers
Sunosi (solriamfetol), a drug marketed by Axsome Therapeutics Inc, met the first endpoint within the “SHARP” research and considerably improved cognitive perform as in comparison with placebo in cognitively impaired sufferers with extreme daytime sleepiness (EDS) related to obstructive sleep apnea (OSA). Sunosi was in comparison with placebo utilizing the Digit Image Substitution Take a look at subtest of the Repeatable Battery for the Evaluation of Neuropsychological Standing (DSST RBANS), in addition to utilizing patient-reported measures of cognitive perform. Within the research, Sunosi replicated earlier findings by considerably decreasing extreme daytime sleepiness signs as in comparison with placebo.
SHARP (Solriamfetol’s Impact on Cognitive Well being in Apnea Contributors Throughout a Randomized Placebo-controlled Research) was a randomized, double-blind, placebo-controlled, crossover, multicenter, trial in 59 sufferers with extreme daytime sleepiness related to OSA, and impaired cognitive perform. Sufferers had been all handled with Sunosi for two weeks, and with placebo for two weeks, with the remedy intervals separated by 1 week of down-titration and washout. Learn extra right here.
Signifier shares eXciteOSA adherence information for gentle sleep apnea
Signifier Medical Applied sciences LLC as we speak launched the outcomes of an evaluation of real-world affected person adherence information for its lead product, eXciteOSA, the first daytime remedy indicated to deal with major loud night breathing and gentle obstructive sleep apnea (OSA).
The information demonstrated that real-world sufferers in the US prescribed eXciteOSA used remedy on over 80% of days over the primary six weeks of remedy. In a launch, Signifier notes that scientific trials and observational research point out 25% to 46% of sufferers should not adherent to PAP for sleep apnea, and there may be additionally proof these with gentle OSA are 34% much less doubtless to be adherent to PAP than these with reasonable/extreme OSA.
Within the white paper, “A descriptive evaluation of objectively monitored real-world adherence to eXciteOSA,” Signifier analyzed information from 3,561 particular person sufferers in the US up till June 2022. The outcomes show that sufferers have used eXciteOSA remedy on over 80% of days in the course of the first six weeks of remedy. Signifier reported that real-world sufferers use remedy for a median of 680 minutes (11:20 hh:mm) inside the first six weeks, representing over 80% of the whole period prescribed (840 minutes). The dataset represents the complete inhabitants of US-based sufferers who began remedy on eXciteOSA over the 15-month interval from April 2021 to June 2022. Learn extra right here.